Form 4: Kymera Therapeutics CBO Noah Goodman Sells Shares

Chief Business Officer Noah Goodman sold 1,347 shares of Kymera Therapeutics common stock at $90 per share.

Summary

• Noah Goodman, Chief Business Officer of Kymera Therapeutics, Inc. (KYMR), sold 1,347 shares of common stock.
• The transaction occurred on April 14, 2026, at a price of $90 per share.
• Following this transaction, the reporting person retains beneficial ownership of 50,195.438 shares.
• The sale was executed under a pre-established Rule 10b5-1 trading plan adopted on December 10, 2025.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sale was executed through a pre-planned, non-discretionary trading program.

Positives

• The sale was conducted via a pre-planned Rule 10b5-1 trading plan, which is a standard mechanism for executives to sell shares without triggering insider trading concerns.

Negatives

• The transaction represents a divestment of equity by a key member of the executive leadership team.

Risks

• Executive stock sales can sometimes be perceived negatively by the market as a signal of management's view on the company's current valuation.

Future Outlook

No forward-looking guidance or operational outlook was provided in this filing.

Industry Context

StockSavvy.ai notes that executive stock sales under 10b5-1 plans are routine in the biotechnology sector and generally do not reflect a change in corporate strategy or fundamental outlook.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans is the industry standard for corporate officers to manage personal liquidity while maintaining regulatory compliance.

Stakeholder Impact

• Minimal impact expected on shareholders as the sale was pre-planned and represents a small portion of the executive's total holdings.

Next Steps

• No future actions or milestones were disclosed in this filing.

Key Dates

Keywords

Kymera Therapeutics, KYMR, Insider Trading, Form 4, Noah Goodman, Biotech, Stock Sale